Assessing the validity of recent estimates of problematic drug use in England
Frisher, Martin; Forsyth, Alasdair

Published in:
Journal of Epidemiology and Community Health

DOI:
10.1136/jech.2008.076844

Publication date:
2009

Document Version
Author accepted manuscript

Link to publication in ResearchOnline

Citation for published version (Harvard):
https://doi.org/10.1136/jech.2008.076844

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details of how to contact us.

Download date: 14. Sep. 2023
Assessing the validity of recent estimates of problematic drug use in England

Martin Frisher & Alasdair Forsyth

Name, Positions & Addresses

Martin Frisher, Senior Lecturer, Department of Medicines Management, Keele University, Staffordshire, ST5 5BG, United Kingdom. E-mail: m.frisher@keele.ac.uk

Alasdair Forsyth, Senior Research Fellow, Scottish Centre for Crime & Justice Research, Glasgow Caledonian University, Glasgow, G4 0BA, United Kingdom E-mail: Alasdair.Forsyth@gcal.ac.uk

Corresponding Author:

Martin Frisher,
Department of Medicines Management,
Keele University, Staffordshire, ST5 5BG,
United Kingdom

e-mail: m.frisher@keele.ac.uk
tel: 01782 583 568
Abstract

The Home Office has recently published estimates which, for first time, provide a “robust national estimate” of the number of problematic drug users (PDU) in England. The 2004/05 and 2005/06 estimates are the highest estimates ever produced for England and coincide with the highest ever Government annual expenditure on combating illicit drug use. This paper reviews a range of data sources that indicate a downwards trend in problematic drug use in recent years. The validity of the estimates is important for drug policy and the paper considers the implications of both increasing and decreasing levels of problematic drug use.
Assessing the validity of recent estimates of problematic drug use in England

Introduction

The Home Office has recently published estimates of the number of problematic drug users (PDU) in England for 2004/05 and 2005/06. The first study report states that the method used “provides for the first time a robust national estimate of this important target group”. Previous estimates are said to be less robust because they “had very wide confidence intervals within which the true estimate might lie”. The 2004/05 and 2005/06 estimates are the highest estimates ever produced for England and coincide with the highest ever annual UK Government’s direct annual expenditure on combating illicit drug use of £1.48 billion in 2005/06.

However, robustness is not just a matter of confidence intervals but of the validity of the data and methods which underlie the estimates. The implication of the 2004/05 and 2005/06 estimates is that problematic drug use is at an all time high. Elsewhere the authors of these estimates discuss a scenario where problematic drug use in the UK may continue to increase to over 1 million by 2025. However, other data sources, described below, indicate a downwards trend in problematic drug use in recent years.

The recent PDU estimates are based on two statistical techniques; the capture recapture method (CRM) and (to a lesser extent) the multiple indicator method (MIM). Both
methods are indirect ways of estimating prevalence and rely on data on known drug users\textsuperscript{5,6}. Indirect methods are generally used for PDU, as direct methods such as population surveys have obvious limitations for this group.

CRM involves examining the overlap between lists of drug users whose identifiers are recorded by agencies such as treatment centres or the police. Essentially, the lower the level of overlap, the higher the estimate. Thus accurate identification of individuals is essential. More sophisticated versions involving multiple samples have also been developed in order to overcome the stringent assumptions which are required when only two-samples are used. MIM is a form of multiple regression analysis in which drug indicators are used to impute estimates in areas where the number of users is unknown. In simple terms, as the level of drug indicators increase, so to does the prevalence estimate.

For CRM to produce valid estimates cases should have equal ‘catchability’ in each source and be uniquely matched among the various data sources. MIM assumes that there is a linear relationship between drug indicators and prevalence and that this relationship is the same in all areas. The underlying robustness or otherwise of these models, therefore depends on whether these assumptions are met.

In practice these assumptions are difficult to verify. An alternative approach to evaluating robustness is to consider the criterion validity of the estimates. Criterion-related validity includes “any validity strategies that focus on the correlation of the
measure being validated with some well-respected outside measure(s) of the same objectives or specifications”7.

One way of assessing the criterion validity of the estimates is to compare trends in prevalence estimates and other measures of problematic drug use. The estimates would have criterion validity if the magnitude and direction of change in PDU prevalence estimates were similar to the change in drug indicators.

National PDU estimates for England are available for 19968, 2001/029,10.. 2004/051 and 2005/062. Three drug indicators have data over the necessary time scale. These are a) the British Crime Survey11, b) the number of drug related deaths12 and c) the number of hospital admissions that are due to drug abuse13. All three of these indicators are potentially less biased than, for example, the number of drug offences which is more likely to be influenced by policy14. For the BCS, the most appropriate indicator is level of class A drug use in the last month.

Table 1 shows that between 1996 and 2001/02, the PDU estimate increased by 27.6%. The average increase in the three indicators was 16.2%. Between 2001/02 and 2004/05, the PDU estimate increased by 13.8% while the average decrease in the three indicators was 6.4%.
Table 1. Drug indicators and EU/Home Office PDU estimates

<table>
<thead>
<tr>
<th>Data</th>
<th>1996</th>
<th>2001/02/02</th>
<th>2004/2005</th>
<th>% change 1996-2001/02</th>
<th>% change 2001/02-2004/05</th>
</tr>
</thead>
<tbody>
<tr>
<td>N of Hospital Episodes due to drug abuse</td>
<td>7,509</td>
<td>8,767</td>
<td>8,684</td>
<td>+16.8</td>
<td>-0.9</td>
</tr>
<tr>
<td>BCS: Class A use in last month</td>
<td>388,941</td>
<td>551,000</td>
<td>473,000</td>
<td>+41.7</td>
<td>-14.2</td>
</tr>
<tr>
<td>(Est. N of users in England and Wales)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of drug related deaths in England</td>
<td>2,721</td>
<td>2,898</td>
<td>2,598</td>
<td>+6.5</td>
<td>-10.4</td>
</tr>
<tr>
<td>Average change in indicators</td>
<td></td>
<td></td>
<td></td>
<td>+16.2</td>
<td>-6.4</td>
</tr>
<tr>
<td>EU/Home Office PDU median estimate for England</td>
<td>225,403</td>
<td>287,670</td>
<td>327,447</td>
<td>+27.6</td>
<td>+13.8</td>
</tr>
</tbody>
</table>

Note: the 1996 and 2001 definition of problematic drug use was ‘current use of illicit opiates, crack-cocaine or benzodiazepines’; 2005 definition was restricted to “use of opiates and/or the use of crack cocaine”.

The direction of change for all drug indicators between 1996 and 2001/02 is in the same direction as the PDU estimates. In contrast between 2001/02 and 2004/05, the PDU estimate increased while the three drug indicators declined.

There is also further evidence that PDU has declined in recent years. The Home Office’s Drug Harm Index (DHI) mirrors the indicators reported here. The DHI incorporates measures of the harms that individuals and society suffer due to drug-related crime, the health impacts arising from drug abuse, and the impact of drug use and dealing on communities. This is achieved by using readily available published data for each of the harms, which are then combined into a single-figure time-series index. In 1998 the index was calibrated at 100, increasing to 120.8 in 2001 and falling to 83.8 in 2005.
If the DHI trend is applied to the PDU estimates, using the 2001/02 estimate as the baseline, the 2005/05 figure would be 200,000, i.e. 40% lower than the Home Office estimate. As this estimate is far outwith the confidence interval of 325,945 – 343,424, the implications are either that the analysis presented here is faulty or that the data on which the 2004/05 estimates are based are not suitable for the statistical methods used.

The validity of the estimates is important for drug policy. If the 2004/05 estimates are valid they suggest that efforts to combat problematic drug use from 2001 to 2005 have not been successful, since the estimated number of problematic drug users has increased by 14% compared to the 2001/02 estimate. It is possible that increasing levels of PDU could coexist with decreasing levels of drug indicators if, for example, harm reduction policies have been effective in reducing the number of drug related deaths. However, one of the authors of the recent estimates has specifically criticised harm reduction policies and has stated that they have “failed”. An alternative scenario, would be that the actual PDU level is significantly lower than the published estimate which is therefore not as “robust” as has been claimed. A recent Swiss study reported that heroin substitution programmes with methadone or buprenorphine) are associated with declining incidence of heroin use in treatment in Switzerland perhaps because the medicalisation of drug addiction has changed the image of heroin such that it is no longer seen as an attractive drug of choice for many young people. Although the authors of the Swiss study are careful to avoid claiming that there is a direct causal association, their detailed analysis is at least consistent with this hypothesis. The analysis presented in the current paper is similarly consistent, but the cultural context of drug use in the UK is very different and
further analysis is required to evaluate the impact of different prevention and treatment strategies.

Declaration of Interest.

MF was one of the authors of the 1996 and 2001/02 studies of problematic drug use.
Policy Implications

While a recent Home Office study has indicated that problematic drug misuse in the England is at an all time high, this paper reviews a range of data which indicate that challenges that problematic drug misuse may well be declining To the best of our knowledge the perception of ever increasing levels of problematic drug misuse is rarely, if ever, challenged in the public health arena. As over £1 billion of public money is being allocated to combat illicit drug use, policy makers should carefully consider the true nature and extent of illicit drug use in the UK.
References


http://www.homeoffice.gov.uk/rds/pdfs06/hosb1506.pdf [accessed 24/01/2008].

12 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is Annual report 2006: the state of the drugs problem in Europe. EMCDDA, Lisbon 2007.


18 McCann, J Get treatment or lose kids, Evening Times, http://www.eveningtimes.co.uk/news/display.var.1794991.0.get_treatment_or_lose_kids.php [accessed 24/01/2008].